Sean R Blackall1, Jae B Hong2, Paul King3, Conroy Wong2, Lloyd Einsiedel4, Marc G W Rémond4, Cindy Woods5, Graeme P Maguire4. 1. School of Medicine and Dentistry, James Cook University, Cairns, QLD, Australia, Australia. 2. Department of Respiratory Medicine, Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand. 3. Monash Respiratory and Sleep Medicine, Monash Medical Centre, Melbourne, VIC, Australia, Australia. 4. Baker Heart and Diabetes Institute, Melbourne, VIC, Australia, Australia. 5. School of Health, University of New England, Armidale, NSW, Australia.
Abstract
BACKGROUND AND OBJECTIVE: Bronchiectasis not associated with cystic fibrosis is an increasingly recognized chronic lung disease. In Oceania, indigenous populations experience a disproportionately high burden of disease. We aimed to describe the natural history of bronchiectasis and identify risk factors associated with premature mortality within a cohort of Aboriginal Australians, New Zealand Māori and Pacific Islanders, and non-indigenous Australians and New Zealanders. METHODS: This was a retrospective cohort study of bronchiectasis patients aged >15 years at three hospitals: Alice Springs Hospital and Monash Medical Centre in Australia, and Middlemore Hospital in New Zealand. Data included demographics, ethnicity, sputum microbiology, radiology, spirometry, hospitalization and survival over 5 years of follow-up. RESULTS: Aboriginal Australians were significantly younger and died at a significantly younger age than other groups. Age- and sex-adjusted all-cause mortality was higher for Aboriginal Australians (hazard ratio (HR): 3.9), and respiratory-related mortality was higher for both Aboriginal Australians (HR: 4.3) and Māori and Pacific Islander people (HR: 1.7). Hospitalization was common: Aboriginal Australians had 2.9 admissions/person-year and 16.9 days in hospital/person-year. Despite Aboriginal Australians having poorer prognosis, calculation of the FACED score suggested milder disease in this group. Sputum microbiology varied with Aspergillus fumigatus more often isolated from non-indigenous patients. Airflow obstruction was common (66.9%) but not invariable. CONCLUSIONS: Bronchiectasis is not one disease. It has a significant impact on healthcare utilization and survival. Differences between populations are likely to relate to differing aetiologies and understanding the drivers of bronchiectasis in disadvantaged populations will be key.
BACKGROUND AND OBJECTIVE:Bronchiectasis not associated with cystic fibrosis is an increasingly recognized chronic lung disease. In Oceania, indigenous populations experience a disproportionately high burden of disease. We aimed to describe the natural history of bronchiectasis and identify risk factors associated with premature mortality within a cohort of Aboriginal Australians, New Zealand Māori and Pacific Islanders, and non-indigenous Australians and New Zealanders. METHODS: This was a retrospective cohort study of bronchiectasispatients aged >15 years at three hospitals: Alice Springs Hospital and Monash Medical Centre in Australia, and Middlemore Hospital in New Zealand. Data included demographics, ethnicity, sputum microbiology, radiology, spirometry, hospitalization and survival over 5 years of follow-up. RESULTS: Aboriginal Australians were significantly younger and died at a significantly younger age than other groups. Age- and sex-adjusted all-cause mortality was higher for Aboriginal Australians (hazard ratio (HR): 3.9), and respiratory-related mortality was higher for both Aboriginal Australians (HR: 4.3) and Māori and Pacific Islander people (HR: 1.7). Hospitalization was common: Aboriginal Australians had 2.9 admissions/person-year and 16.9 days in hospital/person-year. Despite Aboriginal Australians having poorer prognosis, calculation of the FACED score suggested milder disease in this group. Sputum microbiology varied with Aspergillus fumigatus more often isolated from non-indigenous patients. Airflow obstruction was common (66.9%) but not invariable. CONCLUSIONS:Bronchiectasis is not one disease. It has a significant impact on healthcare utilization and survival. Differences between populations are likely to relate to differing aetiologies and understanding the drivers of bronchiectasis in disadvantaged populations will be key.
Authors: Andrew J Collaro; Anne B Chang; Julie M Marchant; Ian B Masters; Leanne T Rodwell; Allan J Takken; Margaret S McElrea Journal: Lung Date: 2020-02-20 Impact factor: 2.584
Authors: Anne B Chang; Siew Moy Fong; Tsin Wen Yeo; Robert S Ware; Gabrielle B McCallum; Anna M Nathan; Mong H Ooi; Jessie de Bruyne; Catherine A Byrnes; Bilawara Lee; Nachal Nachiappan; Noorazlina Saari; Paul Torzillo; Heidi Smith-Vaughan; Peter S Morris; John W Upham; Keith Grimwood Journal: BMJ Open Date: 2019-04-24 Impact factor: 2.692
Authors: Kobi L Schutz; Julie M Marchant; Anne B Chang; Catherine Turner; Mark D Chatfield; Gabrielle B McCallum Journal: Front Pediatr Date: 2019-10-30 Impact factor: 3.418
Authors: Andrew J Collaro; Anne B Chang; Julie M Marchant; Mark D Chatfield; Annette Dent; Tamara Blake; Patsi Mawn; Kwun Fong; Margaret S McElrea Journal: Lung Date: 2021-07-03 Impact factor: 2.584
Authors: Dawn Sibanda; Rosalyn Singleton; John Clark; Christine Desnoyers; Ellen Hodges; Gretchen Day; Gregory Redding Journal: Int J Circumpolar Health Date: 2020-12 Impact factor: 1.228